Bendy tool may make lung cancer surgery quicker and safer
NCT ID NCT07201077
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new bendable surgical tool (SurgeoFlex Grasp) against a standard rigid tool in 100 adults with early-stage lung cancer undergoing keyhole surgery. The goal was to see if the flexible tool makes lymph node removal faster, reduces instrument clashes, and eases surgeon workload. Results could lead to shorter operations, smaller scars, and less pain for future patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Eligibility Criteria Inclusion Criteria * Age 18-70 years, any sex * BMI 18.5-30 kg/m² * Newly diagnosed non-small-cell lung cancer with pre-operative clinical stage cT1-2N0-1M0 * Scheduled to undergo single-port video-assisted thoracoscopic lobectomy with systematic lymph-node dissection * Major organ function sufficient for surgery * Written informed consent provided Exclusion Criteria * Small-cell lung cancer or mixed-type lung cancer * Tumor invasion of main bronchus, chest wall, diaphragm, or major mediastinal vessels * Previous ipsilateral thoracic surgery or prior neoadjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy * Severe cardiopulmonary dysfunction (FEV₁ \<50 % predicted or LVEF \<40 %) * Pregnant or breastfeeding women * Participation in another interventional clinical trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, 510120, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Surgeons could freeze lung tumors from miles away using 5G robots
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?